Fitlife Brands director Seth Yakatan buys $2,519 in company stock

Fitlife Brands director Seth Yakatan purchased 164 shares of FTLF stock for a total of $2,519 on January 15, 2026, as part of a Rule 10b5-1 plan. Despite this insider transaction, the stock has since declined to $8.99, nearing its 52-week low. The company recently reported a 73% revenue increase in Q4 2025, largely due to the Irwin Naturals acquisition, though net income and gross margins faced challenges.

Original reporting
Investing.com · Investing.com
Published Apr 21, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 21, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fitlife Brands director Seth Yakatan buys $2,519 in company stock — source image
Decision brief

The 30-second read

$FTLFNeutralLow
01

Why it matters

The insider purchase amidst a declining stock price suggests insider confidence, but broader financial challenges warrant caution.

02

Market read

Company-specific insider activity with limited immediate impact on broader market or sector.

03

What to watch

Potential upcoming catalysts such as new product launches or strategic initiatives that could reverse current trends.

Relevance 6/10Timing: moderate

Background

Fitlife Brands recently reported strong revenue growth driven by acquisitions, but profitability metrics remain under pressure.

Company-level read

Ticker impact

$FTLFNeutralMedium confidence
Context

The insider purchase by the company's director indicates potential confidence in the company's future prospects, but the recent stock decline suggests market skepticism or external challenges.

Expected impact

Limited immediate impact; potential for short-term stabilization or further decline depending on broader market sentiment.

Evidence & confidence

Insider buying suggests confidence, but the stock's decline and recent financial challenges temper optimism. Technical indicators and market sentiment support a cautious approach.

Market effects

The health and wellness sector may experience mixed sentiment due to company-specific developments.

Minimal regional impact; company-specific news.

Limited global relevance; focused on company and sector.

Counterpoint

Insider buying could signal upcoming positive developments not yet reflected in the stock price.

Key entities

  • Seth Yakatan

    Director of Fitlife Brands who purchased shares.

  • Fitlife Brands

    Health and wellness company operating in the dietary supplements sector.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FitLife Brands Announces Second Quarter 2026 Results

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$UALMed

United Airlines system outage disrupts departures, 418 flights delayed

United Airlines experienced a system outage causing 418 flight delays. The issue affected departing flights and pilot applications, but not in-air flights or United Express services. The airline resolved the outage, attributing it to a technology issue, not cybersecurity. Recent U.S. tech disruptions include JPMorgan Chase's banking service delays and an FAA air traffic control system malfunction.

$BAMed

First permanently assigned F-15EXs touch down at Kadena Air Base

Kadena Air Base in Japan received two permanently assigned F-15EX Eagle II fighter jets, marking the first overseas U.S. base to do so. The Air Force aims to boost airpower in the Pacific, replacing older F-15C/D models. The jets, with advanced avionics and weapons capacity, will support operations with Japan and regional partners. Boeing received a $2.38 billion contract for 22 more F-15EXs, increasing the total to 120.